LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$4.13

-3.65% today

Updated 2026-06-05

Market cap

$329.31M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.12

Dividend yield

—

52W range

$2 – $6

Volume

1.6M

Market cap

$329.31M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.12

Dividend yield

—

52W range

$2 – $6

Volume

1.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-6.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$15.11

+265.86%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -6.75 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-44.61M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-34.18M	$-36.95M	$-80.60M	$-165.67M	$-29.61M
EPS	—	—	—	—	$-2.12
Free cash flow	$-27.67M	$-33.62M	$-71.28M	$-113.29M	$-44.61M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-05-19	TRUITT, JOSEPH	Buy	55,150	—
2026-05-19	THOMAS, FRANK E	Buy	55,150	—
2026-05-19	SHERMAN, JEFFREY W	Buy	55,150	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LRMR	$329.31M	28	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Larimar Therapeutics Inc trades at $4.13. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -6.75, it sits in the distress.

Frequently asked questions

What is Larimar Therapeutics Inc's stock price?

Larimar Therapeutics Inc (LRMR) trades at $4.13.

Is Larimar Therapeutics Inc overvalued?

Larimar Therapeutics Inc carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Larimar Therapeutics Inc (LRMR)?

The 12-month analyst consensus target is $15.11, about 265.9% above the current $4.13. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Larimar Therapeutics Inc's Altman Z-Score is -6.75, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

larimartx.com

Quick metrics

P/S ratio—

ROE-105.04%

Beta0.82

50D MA$4.23

200D MA$4.01

Shares out0.10B

Float0.06B

Short ratio—

Avg volume1.6M

Performance

1 week-20.98%

1 month-32.64%

3 months+9.83%

YTD-14.96%

1 year—

3 years—

5 years—

Compare

LRMR vs LLY →LRMR vs JNJ →LRMR vs ABBV →Stock screener →